A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
Author
Mikhael, JosephBelhadj-Merzoug, Karim
Hulin, Cyrille
Vincent, Laure
Moreau, Philippe
Gasparetto, Cristina
Pour, Ludek
Spicka, Ivan
Vij, Ravi
Zonder, Jeffrey
Atanackovic, Djordje
Gabrail, Nashat
Martin, Thomas G
Perrot, Aurore
Bensfia, Samira
Weng, Qilong
Brillac, Claire
Semiond, Dorothée
Macé, Sandrine
Corzo, Kathryn P
Leleu, Xavier
Date
2021-05-12Journal
Blood Cancer JournalPublisher
Springer NatureType
Article
Metadata
Show full item recordSee at
https://doi.org/10.1038/s41408-021-00478-4http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8116334/
Identifier to cite or link to this item
http://hdl.handle.net/10713/15660ae974a485f413a2113503eed53cd6c53
10.1038/s41408-021-00478-4
Scopus Count
Collections
Related articles
- Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
- Authors: Sherbenou DW, Mark TM, Forsberg P
- Issue date: 2017 Sep
- Isatuximab for the treatment of relapsed/refractory multiple myeloma.
- Authors: Richardson PG, Beksaç M, Špička I, Mikhael J
- Issue date: 2020 Dec
- Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
- Authors: Vozella F, Siniscalchi A, Rizzo M, Za T, Antolino G, Coppetelli U, Piciocchi A, Andriani A, Annibali O, De Rosa L, Cimino G, La Verde G, De Stefano V, Cantonetti M, di Toritto TC, Petrucci MT
- Issue date: 2021 Apr
- Therapeutic potential of isatuximab in the treatment of multiple myeloma: Evidence to date.
- Authors: Richter J, Sanchez L, Thibaud S
- Issue date: 2020 Apr-Jun
- Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
- Authors: Zhang T, Wang S, Lin T, Xie J, Zhao L, Liang Z, Li Y, Jiang J
- Issue date: 2017 May 16